Simplex Trading
GANX icon

Simplex Trading’s Gain Therapeutics GANX Stock Holding History

Simplex Trading’s Portfolio GANX Stock Details GANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.1K Buy
9,900
+5,800
+141% +$10.7K ﹤0.01% 7108
2026
Q1 		$7.95K Sell
4,100
-14,500
-78% -$31.6K ﹤0.01% 7554
2025
Q4 		$59.9K Sell
18,600
-64,100
-78% -$171K ﹤0.01% 5496
2025
Q3 		$146K Buy
+82,700
New +$140K ﹤0.01% 5306
2025
Q2 		– Sell
-1,400
Closed -$2K – 8999
2025
Q1 		$2K Sell
1,400
-5,000
-78% -$11.1K ﹤0.01% 7983
2024
Q4 		$13K Buy
+6,400
New +$12.8K ﹤0.01% 6999
2024
Q2 		– Sell
-300
Closed -$1K – 9122
2024
Q1 		$1K Sell
300
-15,000
-98% -$62.2K ﹤0.01% 8564
2023
Q4 		$49K Buy
15,300
+200
+1% +$556 ﹤0.01% 6094
2023
Q3 		$49K Sell
15,100
-28,100
-65% -$107K ﹤0.01% 5820
2023
Q2 		$193K Sell
43,200
-2,800
-6% -$13.7K ﹤0.01% 4330
2023
Q1 		$221K Buy
+46,000
New +$188K ﹤0.01% 4203

Other funds holding GANX

Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
PCM
Potomac Capital Management New York $147M AUM
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
DCM
DME Capital Management New York $3.91B AUM 36.1% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Simplex Trading's GANX Position: Q2 2026 in Review

Simplex Trading sold out of Gain Therapeutics (GANX) in Q2 2026, closing a stake of 13,439 shares — an estimated $24.8K sold.

Simplex Trading first reported a position in GANX in Q3 2022 and held it in 9 quarters. The position peaked at $154K in Q4 2025. 50 funds tracked by Wall St. Rank hold GANX as of Q2 2026.

  • Simplex Trading reported no remaining Gain Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Simplex Trading sold 13,439 Gain Therapeutics shares in Q2 2026, an estimated $24.8K.
  • Simplex Trading first reported a position in Gain Therapeutics in Q3 2022 and held it in 9 quarters.
  • Simplex Trading's Gain Therapeutics position peaked at $154K in Q4 2025.
  • 50 funds tracked by Wall St. Rank held Gain Therapeutics as of Q2 2026.

Based on Simplex Trading's 13F filing for Q2 2026, filed 12 Aug 2026.